Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.
Loss of physical function in older adults may be, at least in part, explained by sarcopenia, a phenomenon characterized by a reduction in number and size of muscle fibres and by increase in interstitial fat and connective tissue. Lifestyle intervention (i.e. physical activity and nutrition) have shown to impact on sarcopenia. However, several drugs were suggested, with various levels of scientific evidence, to have an impact on muscle outcomes. In this study we reviewed the effect of six classes of drugs on sarcopenia and muscular outcomes in older adults. We decided to focus our review on two commonly drugs which have recently showed promising effects on muscular outcomes in older adults (ACE inhibitors and statins) and on four drugs whose effect on skeletal muscle was already largely studied (creatine, Growth Hormone, testosterone, estrogens and tibolone).
Onder
G
G
Department of Geriatrics, Policlinico A. Gemelli, Catholic University of the Sacred Heart, Rome, Italy.
Della Vedova
C
C
Landi
F
F
D000368:Aged; D000375:Aging / Q000502:physiology*; D045930:Anabolic Agents / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D003401:Creatine / Q000627:therapeutic use; D005838:Genotype; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D009043:Motor Activity / Q000187:drug effects*; D053580:Muscle Strength / Q000187:drug effects*; D018482:Muscle, Skeletal / Q000187:drug effects*; D009652:Norpregnenes / Q000627:therapeutic use; D055948:Sarcopenia / Q000188:drug therapy* / Q000235:genetics
D045930:Anabolic Agents; D000806:Angiotensin-Converting Enzyme Inhibitors; D000924:Anticholesteremic Agents; D006728:Hormones; D009652:Norpregnenes; C027385:tibolone; D003401:Creatine